Literature DB >> 4033697

Reappraisal of temporary levodopa withdrawal ("drug holiday") in Parkinson's disease.

R Mayeux, Y Stern, K Mulvey, L Cote.   

Abstract

Transient withdrawal of therapy has been advocated as a method of dealing with the complications of long-term use of levodopa in the treatment of Parkinson's disease. We retrospectively examined the effect of a 10-day period of levodopa withdrawal, or "drug holiday," in 28 patients. We then compared the subsequent clinical course of these patients over one year with that of 30 other randomly selected, similar patients with Parkinson's disease. In both groups the disease progressed; there was no difference in disease severity, capacity for daily living activities, or total amounts of dopamine agonists eventually used. For some patients, it was possible to reduce dopamine agonists used immediately after the drug holiday without causing deterioration, but a pulmonary embolus and other complications occurred. Subsequent complications related to long-term dopamine-agonist therapy during the follow-up period were similar in the two groups. this investigation indicates that a drug holiday carries some risk and does not improve the efficacy of levodopa therapy or prevent the problems that occur with long-term administration.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4033697     DOI: 10.1056/NEJM198509193131204

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  9 in total

1.  Case report: successful use of rectally administered levodopa-carbidopa.

Authors:  S D Cooper; H A Ismail; C Frank
Journal:  Can Fam Physician       Date:  2001-01       Impact factor: 3.275

2.  Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease.

Authors:  Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-06       Impact factor: 2.745

Review 3.  Current drug therapy for Parkinson's disease. A review.

Authors:  R J Coleman
Journal:  Drugs Aging       Date:  1992 Mar-Apr       Impact factor: 3.923

4.  Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys.

Authors:  N Arai; M Isaji; M Kojima; E Mizuta; S Kuno
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 5.  Non-human primate models of PD to test novel therapies.

Authors:  Marc Morissette; Thérèse Di Paolo
Journal:  J Neural Transm (Vienna)       Date:  2017-04-08       Impact factor: 3.575

Review 6.  Medication non-adherence in the elderly: how big is the problem?

Authors:  Carmel M Hughes
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 7.  Methods of managing levodopa-induced dyskinesias.

Authors:  L T Giron; W C Koller
Journal:  Drug Saf       Date:  1996-06       Impact factor: 5.606

8.  The effects of acute levodopa withdrawal on motor performance and dopaminergic receptor sensitivity in patients with Parkinson's disease.

Authors:  N Turjanski; W Fernandez; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-07       Impact factor: 10.154

Review 9.  The parkinsonism-hyperpyrexia syndrome.

Authors:  Edward J Newman; Donald G Grosset; Peter G E Kennedy
Journal:  Neurocrit Care       Date:  2008-08-20       Impact factor: 3.210

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.